

**REMARKS**

Entry and consideration of this Amendment are respectfully requested.

The claims have been amended to use proper format. The amended claims recite methods rather than drugs for use in a method.

Improper multiple dependencies have also been corrected. New claims 30-39 claim embodiments deleted due to correction of improper multiple dependencies.

**Response to Restriction Requirement**

In response to the Restriction Requirement, Applicant elects the compound of claim 17, without traverse.

Claims 1-5, 7-17 and 30-39 read on the elected compound.

Applicant reserves the right to file a Divisional Application directed to non-elected subject matter.

The cited reference does not teach or suggest that chymase inhibitors can be used to improve, prevent and/or treat glucose intolerance.

Allowance is respectfully requested. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

PRELIMINARY AMENDMENT  
AND RESPONSE TO RESTRICTION REQUIREMENT  
Application No.: 10/568,711

Attorney Docket No.: Q93208

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

  
Susan J. Mack  
Registration No. 30,951

Date: February 11, 2008